Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Threshold Pharmaceuticals Clear all
Completed Phase 3 Interventional Results available

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

NCT01746979
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions
TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W)
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 28, 2026, 3:59 PM EDT
Not listed Phase 1Phase 2 Interventional

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

NCT01522872
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib, TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
Monterey, California • Tampa, Florida • Scarborough, Maine + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

NCT01440088
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
TH-302 in Combination with Doxorubicin, Doxorubicin
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
15 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
44
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional Results available

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

NCT02047500
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TH-302, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Pazopanib Plus TH-302

NCT01485042
View directory record Official record
Conditions
Solid Tumors
Interventions
Pazopanib and TH-302
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 28, 2026, 3:59 PM EDT
Not listed Phase 1 Interventional

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

NCT02020226
View directory record Official record
Conditions
Solid Tumors
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Tucson, Arizona • Yuma, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

NCT00096707
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer
Interventions
2-deoxy-D-glucose (2DG)
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Miami, Florida • Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00237536
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Lonidamine
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
65 Years to 80 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
34
States / cities
Tucson, Arizona • Atherton, California • Culver City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 28, 2026, 3:59 PM EDT
Not listed Phase 1 Interventional

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160
View directory record Official record
Conditions
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Interventions
Evofosfamide, Ipilimumab
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

NCT00743379
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 28, 2026, 3:59 PM EDT
Not listed Phase 1 Interventional

TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

NCT01721941
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Phase I dose level 1, Phase I Dose level 2, Phase I Dose level 3
Drug
Lead sponsor
Scripps Clinic Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

NCT01149915
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Advanced Myelofibrosis
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

NCT00099294
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
23
States / cities
Los Angeles, California • Denver, Colorado • Torrington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 28, 2026, 3:59 PM EDT
Not listed Phase 1 Interventional

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

NCT01381822
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors, Pancreatic Neuroendocrine Tumors
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Goshen, Indiana • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

NCT00495144
View directory record Official record
Conditions
Tumors, Hypoxia
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

NCT00102752
View directory record Official record
Conditions
Neoplasms, Pancreatic Neoplasms
Interventions
Glufosfamide, Gemcitabine
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Tucson, Arizona • Indianapolis, Indiana • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

NCT01497444
View directory record Official record
Conditions
Kidney Cancer, Liver Cancer
Interventions
hypoxia-activated prodrug TH-302, sorafenib tosylate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

NCT00441467
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Glufosfamide
Drug
Lead sponsor
Eleison Pharmaceuticals LLC.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 28, 2026, 3:59 PM EDT